Used in the treatment of inflammatory and autoimmune diseases, this antibody targets AOC3 (also known as VAP1), a protein involved in leukocyte trafficking. By inhibiting VAP1, it reduces the migration of immune cells into tissues, thereby dampening inflammation. It has shown potential in conditions such as rheumatoid arthritis, diabetic nephropathy, and liver fibrosis. Currently under investigation in clinical trials for its therapeutic effects in chronic inflammatory disorders.